SCHEMBL6985547

SCHEMBL6985547

O=S(=O)(Nc1ccc2c(c1)CCCN2)c1ccccc1CCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
BRD4 O60885 6/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
CREBBP Q92793 1/20 0.37
MLNR O43193 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
DRD3 P35462 1/20 0.36
ACHE P22303 1/20 0.36
METAP2 P50579 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6980011 0.80 BRD4 (0.58) CA12CA1CA2CA9BRD4
SCHEMBL6984820 0.79 HTR6 (0.61) HTR6CA12CA1CA2CA9
SCHEMBL6984534 0.78 MLNR (0.53) CA12CA1CA2CA9BRD4
SCHEMBL6979787 0.78 BRD4 (0.39) BRD4KDM4EMAPTPKMCREBBP
SCHEMBL6983095 0.78 BRD4 (0.51) HTR6BRD4HDAC1
SCHEMBL31681377 0.75 EIF2AK2 (0.54) HTR6CA12CA1CA2CA9
SCHEMBL6976538 0.72 PKM (0.65) HTR6CA12CA1CA2CA9
SCHEMBL2229992 0.72 HTR2C (0.61) CA12CA1CA2CA9BRD4
SCHEMBL7982796 0.71 HTR6 (0.68) HTR6BRD4PKMHTR2CHDAC3
SCHEMBL11698451 0.71 CA12 (0.54) CA12CA1CA2CA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed